Evidence map›Paper›PMID 39403925›Full record

ArticleThe Journal of clinical investigation2024

PRMT5: splicing up tolerance.

Rathan Kumar, Parvathi Ranganathan

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rathan KumarDivision of Hematology, Department of Internal Medicine, Comprehensive Cancer Center and.
Parvathi RanganathanDivision of Hematology, Department of Internal Medicine, Comprehensive Cancer Center and.

Funding

Developing novel therapies to improve blood stem cell transplantation outcomesR01HL163849 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI DORRANCE, ADRIENNE M., GARZON, RAMIRO · 2022 to 2025
$2.7M
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHDR01CA252469 · NCI · OHIO STATE UNIVERSITY · PI CHOE, HANNAH, RANGANATHAN, PARVATHI · 2021 to 2025
$2.0M
NCI NIH HHS R01 CA252469NHLBI NIH HHS R01 HL163849
6 · The paper itself

Abstract

Expression of tissue-restricted antigens (TRAs) within the thymus is critical for the establishment of self-tolerance; however, exact mechanisms regulating the expression of TRAs has proven more complex than previously appreciated. In this issue of the JCI, Muro et al. identify a central role for protein arginine methyltransferase 5 (PRMT5) in posttranscriptional regulation of TRAs and thereby central tolerance. Using conditional KO mice, the authors showed that thymic deficiency of Prmt5 predisposed mice to developing autoimmune diseases while enhancing antitumor efficacy. These studies provide insight into the role of PRMT5 in shaping the T cell repertoire with implications for the development of therapies.

Indexed as

Mice, KnockoutProtein-Arginine N-MethyltransferasesAnimalsAutoimmune DiseasesHumansImmune ToleranceMiceThymus GlandT-LymphocytesPrmt5 protein, mouseProtein-Arginine N-Methyltransferases

Identifiers

PMID39403925
PMCPMC11473145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.